EGX
9.00 EGP
+12.50%From 3 to 6 months
Buy stock at the current price
June 13, 2025 at 11:59:59 PM
Medium
85.00%
12.00%
Ibnsina Pharma has demonstrated robust financial performance, with a 64.49% increase in revenue in 2024, reaching EGP 55.84 billion, and a 187.51% rise in earnings to EGP 497.80 million. The company's strong market position in Egypt's pharmaceutical distribution sector, coupled with its extensive network and services, positions it well for continued growth.
The stock has shown significant growth, with a 166.67% increase over the past year and a 26.18% rise in the past month, indicating strong market confidence.
The Egyptian pharmaceutical market is experiencing growth due to increasing healthcare demands and government initiatives to improve healthcare infrastructure. Ibnsina Pharma's strategic position allows it to capitalize on these favorable economic conditions.
Ibnsina Pharma is a leading pharmaceutical distributor in Egypt, serving both private and public sectors, including retail chains, independent pharmacies, wholesalers, hospitals, and healthcare institutions. Its comprehensive services, such as warehousing, logistics, marketing solutions, importation, packaging, and market research, enhance its competitive edge.
Ibnsina Pharma's impressive financial growth, dominant market position, and favorable economic environment suggest a promising investment opportunity with moderate risk and potential for substantial returns.
- Strong financial growth with significant revenue and earnings increases.
- Dominant position in Egypt's pharmaceutical distribution market.
- Comprehensive service offerings enhance competitive advantage.
- Favorable economic conditions support continued growth.
